hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

Supreme Court Gene Ruling Benefits Biotech, Breast Cancer Research [USA]

Author: Megan McGrath, Voice of America, Published on: 13 June 2013

Everyone has BRCA genes in their cells. If you are a woman and one of your BRCA gene copies has a mutation, your risk of developing breast cancer is very high - up to 87 percent in some cases…Myriad Genetics Inc. was the first to discover the healthy, normal code of BRCA. Myriad developed [a breast cancer] test, and won patent protection for it and the original BRCA gene. Thursday, in a case against Myriad by the ACLU, the Supreme Court decreed that genes can no longer be patented, invalidating Myriad’s intellectual claim to the BRCA code…According to Dr. Marisa Weiss,…this could mean new research, cures and testing for women with BRCA mutations, and for cancer patients.

Read the full post here

Related companies: Myriad Genetics